- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The importance of being CAFs (in cancer resistance to targeted therapies) ; volume:41 ; number:1 ; day:3 ; month:11 ; year:2022 ; pages:1-16 ; date:12.2022
Journal of experimental & clinical cancer research ; 41, Heft 1 (3.11.2022), 1-16, 12.2022
- Creator
-
Rizzolio, Sabrina
Giordano, Silvia
Corso, Simona
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-022-02524-w
- URN
-
urn:nbn:de:101:1-2023011821051357615408
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:23 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rizzolio, Sabrina
- Giordano, Silvia
- Corso, Simona
- SpringerLink (Online service)
Other Objects (12)
Evolution of resistance to MAPK-targeted therapies
Resistance to targeted therapies in acute myeloid leukemia
Resistance to targeted therapies: delving into FLT3 and IDH
Targeted therapies for cancer
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia
The role of microRNAs in resistance to targeted therapies in breast cancer
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis
Developing innovative targeted therapies for China
Evolution of resistance to MAPK-targeted therapies
Resistance to targeted therapies in acute myeloid leukemia
Resistance to targeted therapies: delving into FLT3 and IDH
Targeted therapies for cancer
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia
The role of microRNAs in resistance to targeted therapies in breast cancer
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis
Developing innovative targeted therapies for China
Evolution of resistance to MAPK-targeted therapies
Resistance to targeted therapies in acute myeloid leukemia
Resistance to targeted therapies: delving into FLT3 and IDH
Targeted therapies for cancer
"Targeted therapies" beim nichtkleinzelligen Bronchialkarzinom
Targeted therapies for myeloproliferative neoplasms
Targeted Therapies in Pediatric Oncology
Importance of Minimal Residual Disease in the Era of Targeted Therapies in Chronic Lymphocytic Leukemia
The role of microRNAs in resistance to targeted therapies in breast cancer
HO-1 drives autophagy as a mechanism of resistance against HER2-targeted therapies
Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis